Related Experiment Video

Updated: Jul 16, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase

Marcella Priulla1, Angela Calastretti, Paola Bruno

  • 1Department of Pharmacology, University of Milan, Milan, Italy.

The Prostate
|March 22, 2007
PubMed
Abstract

Insights

Targeting Akt in PTEN-mutated prostate cancer enhances taxol

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Prostate cancer often involves PTEN mutations, leading to PI3K/Akt/mTOR pathway activation.
  • This activation contributes to therapeutic resistance, particularly to chemotherapy.
  • Targeting key nodes in this pathway is a strategy to overcome resistance.

Purpose of the Study:

  • To investigate the efficacy of silencing Akt (a key kinase in the PI3K/Akt/mTOR pathway) in overcoming taxol resistance in prostate cancer cells.
  • To determine if PTEN mutation status influences the response to Akt silencing and taxol treatment.

Main Methods:

  • Utilized siRNA to silence Akt expression in various cell lines, including those with wild-type and mutated PTEN.
  • Assessed chemosensitization to taxol (an antitubule agent) in cells with silenced Akt.
  • Compared treatment effects in cells engineered to express constitutively active Akt (CA-Akt) or dominant-negative Akt (DN-Akt) versus endogenous Akt.

Main Results:

  • Akt silencing significantly sensitized drug-resistant cells (CA-Akt) to taxol, while having minimal effect on drug-sensitive cells (DN-Akt) or wild-type cells.
  • The chemosensitizing effect of Akt silencing was more pronounced in prostate cancer cell lines with mutated PTEN compared to those with wild-type PTEN.
  • Akt siRNA potentiated taxol-induced apoptosis preferentially in PTEN-mutated cell lines.

Conclusions:

  • Silencing Akt enhances the antitumor efficacy of taxol in PTEN-mutated prostate cancer.
  • Prostate cancer cells with wild-type PTEN did not exhibit significant chemosensitization to taxol upon Akt silencing.

More Related Videos

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...